MD Anderson and ARTIDIS form strategic alliance to advance nanomechanical technology platform

Immunotherapy for pediatric osteosarcoma with lung metastases after resection shows positive data

OS Therapies Inc. announced positive data from a phase IIb clinical trial (NCT04974008) of OST-HER2 (OST31-164)—the company’s HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma.

January 17, 2025

Vol.51 No.02

Drugs & Targets

MAIA Biotechnology, BeiGene announce clinical supply agreement

MAIA Biotechnology Inc. and BeiGene entered into a clinical supply agreement to assess the efficacy of THIO, MAIA Biotechnology’s small molecule telomere-targeting anticancer agent, in combination with BeiGene’s immune checkpoint inhibitor tislelizumab, in three cancer indications. The single-arm pivotal phase II trials will study the drug combination in hepatocellular carcinoma, small cell lung cancer, and colorectal cancer.

January 17, 2025

Vol.51 No.02

Clinical Roundup

Researchers develop system which helps overcome CAR T-cell resistance in preclinical models

Researchers from City of Hope, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, the University of Pennsylvania, and NIH have developed a way to add features to T cells to help them overcome mechanisms of chimeric antigen receptor T-cell therapy resistance. The new system is outlined in a paper published in Nature Biomedical Engineering.

January 10, 2025

Vol.51 No.01

Clinical Roundup

Physicians with the Lymphoma Research Foundation present research focused on immunotherapy, disparities at ASH 2024

Several physicians and lymphoma experts who work closely with the Lymphoma Research Foundation presented abstracts at the 66th annual ASH Annual Meeting and Exposition in San Diego, CA on Dec. 7-10, 2024.

January 10, 2025

Vol.51 No.01

Drugs & Targets

FDA approves Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma

FDA approved Unloxcyt (osibelimab-ipdl), a programmed death ligand-1 blocking antibody, for adults with metastatic cutaneous squamous cell carcinoma or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

January 10, 2025

Vol.51 No.01

In Brief

MD Anderson’s Lauren Averett Byers receives TAMEST O’Donnell Award

Lauren Averett Byers, professor of thoracic/head & neck medical oncology at the University of Texas MD Anderson Cancer Center, received the 2025 Edith and Peter O’Donnell Award in Medicine from the Texas Academy of Medicine, Engineering, Science and Technology. The award recognizes her fundamental discoveries and contributions to identifying novel therapeutic strategies for small cell lung cancer, which have paved the way for personalized treatments, even in the most highly recalcitrant cancers.

December 13, 2024

Vol.50 No.46

MD Anderson and ARTIDIS form strategic alliance to advance nanomechanical technology platform

YOU MAY BE INTERESTED IN

Immunotherapy for pediatric osteosarcoma with lung metastases after resection shows positive data

MAIA Biotechnology, BeiGene announce clinical supply agreement

Researchers develop system which helps overcome CAR T-cell resistance in preclinical models

Physicians with the Lymphoma Research Foundation present research focused on immunotherapy, disparities at ASH 2024

FDA approves Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma

MD Anderson’s Lauren Averett Byers receives TAMEST O’Donnell Award

Renew today!

Subscriber content

Never miss an issue!

Login